Contact

 

Prof. Michael Platten, MD
Phone: +49 6221 566804

E-mail: michael.platten@uni-heidelberg.de

 

 

Understanding Multiple Sclerosis...

 

will help succeed in brain Tumor immunotherapy.

CCU Neuroimmunology and Brain Tumor Immunology

DKFZ
 
 
 

Our group/department has:

The translational research of the group focuses on immunosuppressive catabolism of tryptophan and novel targets for active immunotherapy of gliomas.

The group has:

  • identified and patented a synthetic tryptophan catabolite capable of inducing regulatory T cells (Science 2005, 310:850-855, PCT/US2006/001241). This orally active compound is now in clinical trials in patients with autoimmune diseases (NCT01052987, NCT00882024).

  • developed and patented novel tools to monitor tryptophan catabolism on a single cell level (PLoS Biol 2007, IPC8: AC12Q102FI). These activities have resulted in the integration into the new SFB 938 Collaborative Research Group “Micromilieu control of immunological reactivity” with a joint project with the CCU Neurooncology.

  • identified key immunosuppressive activities of commonly used drugs that interfere with the angiotensin system indicating that these drugs may be useful for the treatment of autoimmune diseases (Proc Natl Acad Sci 2009, 106:14948-14953; J Clin Invest 2010, 120:2782-94).

  • identified and patented a tryptophan catabolic pathway that is constitutively active in tumors and drives tumor formation via direct and host-mediated effects via the xenobiotic aryl hydrocarbon receptor. This is the first identification of an endogenous ligand for this receptor in a pathophysiologically relevant context (Nature 2011, 478:197-203).

  • developed and patented a peptide vaccine targeting mutant IDH1 in gliomas with companion diagnostic to evaluate specific T- and B cell responses to mutant IDH1 in patients (WO 2013/102641 A1)

2010 – 2013

  • Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011). An endogenous ligand of the human aryl hydrocarbon receptor promotes tumor formation. Nature 478:197-203.

  • Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012 Jul;13(7):707-15.

  • Sahm F, Oezen I, Opitz CA, Radlwimmer B, von Deimling A, Ahrendt T, Adams S, Bode, HB, Guillemin G, Wick W, Platten M (2013). The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Res 73:1-10.

  • Lanz TV, Becker S, Osswald M, Bittner S, Schuhmann MK, Opitz CA, Gaikwad S, Wiestler B, Litzenburger UM, Sahm F, Ott M, Iwantscheff S, Grabitz C, Mittelbronn M, von Deimling A, Winkler F, Meuth SG, Wick W, Platten M (2013). Endothelial protein kinase Cβ as a therapeutic target stabilizing blood brain barrier disruption in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 110:14735-14740.

  • Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, Hodecker S, Osswald M, Meisner C, Hielscher T, Rübmann P, Pfenning PN, Ronellenfitsch M, Kempf T, Schnölzer M, Abdollahi A, Lang F, Bendszus M, von Deimling A, Winkler F, Weller M, Vajkoczy P, Platten M, Wick W. (2014) mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):409-14.

  • A method of modulating cellular activity and agents useful for the same
    US 7531575 B2

  • Method of modulating T cell functioning
    WO 2006076580 A2

  • Trp/his exchange and kynurenine induced trp transport
    WO 2008108994 A1

  • Means and methods for treating and/or preventing natural Ahr ligand-dependent cancer WO 2013034685 A1

  • Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers
    WO 2013/102641 A1

  • Bayer Early Excellence Award in Science in Biology (C. Opitz, 2013)

  • Sybille Assmus Award (C. Opitz, 2012)

  • Sir Hans Krebs Award (M. Platten, 2012)

  • Hella Bühler Award (C. Opitz, 2012)

  • Waltraud Lewenz Award (C. Opitz, 2011)

  • Chica and Heinz Schaller Award (M. Platten, 2011)

  • Heinrich Pette Award of the German Neurological Society (M. Platten, 2010)